Saba Fooladi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saba Fooladi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hamed Akbari
Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
2 shared publications - Erfan Sadeghi
Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Gholamreza Asadikaram
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Hamid Aria
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Hossein Fallah
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Mohammad Masoumi
Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication
Latest Publications
- Open Access
Estradiol, des-acylated, and total ghrelin levels might be associated with epithelial ovarian cancer in postmenopausal women
Background: The present study aimed to investigate the association between estradiol, acylated, des-acylated, total ghrelin levels along with pathological parameters and epithelial ovarian cancer (EOC) odds in postmenopausal women. Methods: A case-control study was carried out on 45 EOC patients and 33 age-matched postmenopausal women as the control group. Plasma levels of estradiol, acylated, des-acylated, and total ghrelin were measured by ELISA method. Results: Estradiol’s plasma levels were significantly higher in EOC patients compared to control women ( P < 0.001). Although acylated, des-acylated, and total ghrelin levels were not associated with EOC in logistic regression models, estradiol levels were significantly related to the increase in EOC odds (OR: 1.083, 95% CI: 1.037-1.13, P < 0.001). However, estradiol levels in the two first quartiles (Q 1 , Q 2 ) were associated with decreased odds of EOC (OR: 0.011, 95% CI: 0.001-0.118, P < 0.001, and OR: 0.030, 95% CI: 0.003-0.284, P = 0.002, respectively). For those patients in the third quartile of plasma des-acylated and total ghrelin compared to those in the highest (Q4), the multivariate odds ratios of EOC were respectively 0.192 and 0.25. Conclusions: In conclusion, higher concentrations of des-acylated and total ghrelin might be associated with the decreased EOC odds. Furthermore, the findings suggest that high levels of estradiol might be a potential odds factor in EOC, however, lower estradiol levels may have a protective effect on EOC development.
Open AccessEstradiol, des-acylated, and total ghrelin levels might be associated with epithelial ovarian cancer in postmenopausal women
Background: The present study aimed to investigate the association between estradiol, acylated, des-acylated, total ghrelin levels along with pathological parameters and epithelial ovarian cancer (EOC) odds in postmenopausal women. Methods: A case-control study was carried out on 45 EOC patients and 33 age-matched postmenopausal women as the control group. Plasma levels of estradiol, acylated, des-acylated, and total ghrelin were measured by ELISA method. Results: Estradiol’s plasma levels were significantly higher in EOC patients compared to control women ( P < 0.001). Although acylated, des-acylated, and total ghrelin levels were not associated with EOC in logistic regression models, estradiol levels were significantly related to the increase in EOC odds (OR: 1.083, 95% CI: 1.037-1.13, P < 0.001). However, estradiol levels in the two first quartiles (Q 1 , Q 2 ) were associated with decreased odds of EOC (OR: 0.011, 95% CI: 0.001-0.118, P < 0.001, and OR: 0.030, 95% CI: 0.003-0.284, P = 0.002, respectively). For those patients in the third quartile of plasma des-acylated and total ghrelin compared to those in the highest (Q4), the multivariate odds ratios of EOC were respectively 0.192 and 0.25. Conclusions: In conclusion, higher concentrations of des-acylated and total ghrelin might be associated with the decreased EOC odds. Furthermore, the findings suggest that high levels of estradiol might be a potential odds factor in EOC, however, lower estradiol levels may have a protective effect on EOC development.
- Open Access
- 14 December 2018
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 18 (1) , 1-7
Association of Klotho gene polymorphism with hypertension and coronary artery disease in an Iranian population
Klotho, possibly an age-regulating protein, is considered an important factor contributing to the lifespan and pathophysiology of hypertension and coronary artery disease (CAD). The present study was carried out aiming to investigate the association of Klotho-rs564481 (C1818T) gene polymorphism with hypertension and CAD. A total of 286 CAD-suspicious subjects were entered into this case-control study. The polymorphism was investigated in hypertensive patients with no CAD (H-Tens, n = 60); hypertensive patients with CAD (CAD + H-Tens, n = 95); CAD patients with no hypertension (CAD, n = 61); and non-hypertensive non-CAD subjects, which were regarded as the control group (Ctrl, n = 70). Genotype and allele frequencies were assessed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. A significant difference was found in allele frequency of Klotho C1818T among the four research groups (P = 0.03). It was also found that wild-type homozygote subjects were negatively associated with hypertension as compared to heterozygote ones (OR = 0.07 [95% CI: 0.008–0.69] P = 0.02). Moreover, in the subgroups older than 57 years old, dominant genetic model demonstrated a negative association with CAD combined with hypertension (OR = 0.31 [95% CI: 0.10–0.95] P = 0.04). In conclusion, Klotho C1818T variant may be associated with a decreased risk of hypertension. Moreover, aging enhanced positive effects of the Klotho polymorphism on CAD combined with hypertension, indicating the possibility that the KLOTHO gene might play a part in the age-related occurrence of CAD combined with hypertension.
- 14 December 2018
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 18 (1) , 1-7
Open AccessAssociation of Klotho gene polymorphism with hypertension and coronary artery disease in an Iranian population
Klotho, possibly an age-regulating protein, is considered an important factor contributing to the lifespan and pathophysiology of hypertension and coronary artery disease (CAD). The present study was carried out aiming to investigate the association of Klotho-rs564481 (C1818T) gene polymorphism with hypertension and CAD. A total of 286 CAD-suspicious subjects were entered into this case-control study. The polymorphism was investigated in hypertensive patients with no CAD (H-Tens, n = 60); hypertensive patients with CAD (CAD + H-Tens, n = 95); CAD patients with no hypertension (CAD, n = 61); and non-hypertensive non-CAD subjects, which were regarded as the control group (Ctrl, n = 70). Genotype and allele frequencies were assessed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. A significant difference was found in allele frequency of Klotho C1818T among the four research groups (P = 0.03). It was also found that wild-type homozygote subjects were negatively associated with hypertension as compared to heterozygote ones (OR = 0.07 [95% CI: 0.008–0.69] P = 0.02). Moreover, in the subgroups older than 57 years old, dominant genetic model demonstrated a negative association with CAD combined with hypertension (OR = 0.31 [95% CI: 0.10–0.95] P = 0.04). In conclusion, Klotho C1818T variant may be associated with a decreased risk of hypertension. Moreover, aging enhanced positive effects of the Klotho polymorphism on CAD combined with hypertension, indicating the possibility that the KLOTHO gene might play a part in the age-related occurrence of CAD combined with hypertension.